Concerning the existence of a suppressor mechanism, "4-s", in the unanesthetized human.

R. Myers,J. Knott,M. Skultety,R. Imler

Abstract:

What problem does this paper attempt to address?

Molecular Detection of Isoniazid, Rifampin and Ethambutol Resistance to M. Tuberculosis and M. Bovis in Multidrug Resistant Tuberculosis (MDR-TB) Patients in Pakistan.

Saba Munir,Nasir Mahmood,Saman Shahid,Muhammad Idrees Khan

DOI: https://doi.org/10.1016/j.micpath.2017.07.005

IF: 3.848

2017-01-01

Microbial Pathogenesis

Abstract:The various aspects of MDR-TB, type of pathogen, different drug sensitive methods and mutation (s) in specific genes were determined. The histone-like protein (hupB) gene of M. tuberculosis was targeted by using primer sets: N & S and M & S (produced 645 bp & 318 bp fragment respectively). The most significant risk factors were the poverty and male gender of ages 11-25 years. All samples were detected as M. tuberculosis. By Drug Proportion method, the highest percentage (37%) was found resistant to only Rifampin. By MGIT method, the highest percentage (82.2%) was found resistant with the triple combination (Rifampin-RIF + Isoniazid-INH + Ethambutol-EMB) of the drugs. The highest mutations (76.92%) were found in gene rpoB (codon 531) in MDR TB patients. By, MAS-PCR, the highest percentage (34%) were found resistant to combination (INH + RIF) of the drugs. Minimum samples were resistant to RIF and RIF + INH drugs by MGIT, while proportionate results were observed from MAS-PCR and DP. Moreover, by MAS-PCR mutation in gene embB (306) caused EMB resistance (51.64%). We found that M. tuberculosis was the main cause of MDR-TB. Our findings may further be used for an early diagnosis of multi-drug resistant tuberculosis. (C) 2017 Elsevier Ltd. All rights reserved.
Targeted next-generation sequencing of Mycobacterium tuberculosis from patient samples: lessons learned from high drug-resistant burden clinical settings in Bangladesh

Mohammad Khaja Mafij Uddin,Andrea Maurizio Cabibbe,Rumana Nasrin,Arash Ghodousi,Fahim Alam Nobel,S. M. Mazidur Rahman,Shahriar Ahmed,Md. Fahim Ather,S. M. Abdur Razzaque,Md. Abu Raihan,Pronab Kumar Modak,Jean Luc Berland,Wayne Van Gemert,Sardar Munim Ibna Mohsin,Daniela Maria Cirillo,Sayera Banu

DOI: https://doi.org/10.1080/22221751.2024.2392656

2024-08-27

Emerging Microbes & Infections

Abstract:Lack of appropriate early diagnostic tools for drug-resistant tuberculosis (DR-TB) and their incomplete drug susceptibility testing (DST) profiling is concerning for TB disease control. Existing methods, such as phenotypic DST (pDST), are time-consuming, while Xpert MTB/RIF (Xpert) and line probe assay (LPA) are limited to detecting resistance to few drugs. Targeted next-generation sequencing (tNGS) has been recently approved by WHO as an alternative approach for rapid and comprehensive DST. We aimed to investigate the performance and feasibility of tNGS for detecting DR-TB directly from clinical samples in Bangladesh. pDST, LPA and tNGS were performed among 264 sputum samples, either rifampicin-resistant (RR) or rifampicin-sensitive (RS) TB cases confirmed by Xpert assay. Resistotypes of tNGS were compared with pDST, LPA and composite reference standard (CRS, resistant if either pDST or LPA showed a resistant result). tNGS results revealed higher sensitivities for rifampicin (RIF) (99.3%), isoniazid (INH) (96.3%), fluoroquinolones (FQs) (94.4%), and aminoglycosides (AMGs) (100%) but comparatively lower for ethambutol (76.6%), streptomycin (68.7%), ethionamide (56.0%) and pyrazinamide (50.7%) when compared with pDST. The sensitivities of tNGS for INH, RIF, FQs and AMGs were 93.0%, 96.6%, 90.9%, and 100%, respectively and the specificities ranged from 91.3 to 100% when compared with CRS. This proof of concept study, conducted in a high-burden setting demonstrated that tNGS is a valuable tool for identifying DR-TB directly from the clinical specimens. Its feasibility in our laboratory suggests potential implementation and moving tNGS from research settings into clinical settings.

immunology,infectious diseases,microbiology
Restricted transition probabilities and their applications to some problems in the dynamics of biological populations.

C. Mode

DOI: https://doi.org/10.1007/BF02476813

1966-09-01

The Bulletin of Mathematical Biophysics

Abstract:
New Zealand's neurologist workforce: a pragmatic analysis of demand, supply and future projections.

A. Ranta,Priyesh Tiwari,J. Mottershead,D. Abernethy,Mark Simpson,K. Brickell,Christopher Lynch,E. Walker,R. Frith

2015-08-07

Abstract:AIMS To estimate current and future specialist neurologist demand and supply to assist with health sector planning. METHODS Current demand for the neurology workforce in New Zealand was assessed using neuroepidemiological data. To assess current supply, all New Zealand neurology departments were surveyed to determine current workforce and estimate average neurologist productivity. Projections were made based on current neurologists anticipated retirement rates and addition of new neurologists based on current training positions. We explored several models to address the supply-demand gap. RESULTS The current supply of neurologists in New Zealand is 36 full-time equivalents (FTE), insufficient to meet current demand of 74 FTE. Demand will grow over time and if status quo is maintained the gap will widen. CONCLUSIONS Pressures on healthcare dollars are ever increasing and we cannot expect to address the identified service gap by immediately doubling the number of neurologists. Instead we propose a 12-year strategic approach with investments to enhance service productivity, strengthen collaborative efforts between specialists and general service providers, moderately increase the number of neurologists and neurology training positions, and develop highly skilled non-specialists including trained.
Proceedings: Contraceptive steroids and breast cancer.

J. Spencer,R. Millis,J. Hayward

1976-08-01

Abstract:
The molecular basis for prognosis of isoniazid resistance in Mycobacterium tuberculosis

Siavash J Valafar,Aram A Valafar,Wael Elmaraachli

DOI: https://doi.org/10.1101/2024.09.21.24314105

2024-09-23

Abstract:Tuberculosis (TB), a disease that kills 1.5 million people every year, is a major global public health concern. The emergence of drug resistance in M. tuberculosis, the obligate pathogen of TB is a major challenge. The emergence of resistance seems to follow an order that might be exploited for novel therapeutic strategies. In most cases resistance to isoniazid (INH) emerges first, followed by rifampicin, then either pyrazinamide or ethambutol, and finally followed by resistance to second-line drugs. For this reason, it is thought that prevention of emergence of INH resistance may help the prevention of resistance to other drugs. In this manuscript we present the prognostic potential of specific mutations in predicting the emergence of the three most common canonical INH resistance (katG315, inhA-15, and inhA-8) with the hope that majority of resistance cases can be predicted and avoided. Here we present evidence that resistance to INH occurs in steps that in most cases follow specific evolutionary trajectory. Identifying these steps can therefore be used to predict and avoid the most common INH resistance mechanism. In our approach, we used genomic and phenotypic data from over 16,000 samples collected by two large databases, the TB Portals and the CRyPTIC consortium. We used classical sensitivity and specificity values as well as a deep learning neural models to identify promising predictive mutations using TB Portals data. We then tested the prognostic potential of the identified mutations using the CRyPTIC consortium data. Here we report two mutations (Rv1258c 581 indel & mshA A187V) as those carrying the highest potential for predicting the emergence of the three canonical mutations (accuracy of 73% and specificity of 96%). Our results point to a stepwise evolutionary trajectory toward the emergence of the three canonical mutations. Furthermore, the high negative predictive values provide an opportunity for clinicians to continue using INH in new regiments designed for nonresponsive patients whose samples do not contain the two precursor mutations. Finally, we present testable hypotheses describing the role of the precursor mutations in emergence of the three canonical mutations and the predicted trajectories. Mutagenesis experiments can confirm these hypotheses. Additional time course samples and analysis will undoubtedly uncover additional prognostic markers for other trajectories toward high-level INH resistance.
Molecular epidemiology of isoniazid-resistant M. tuberculosis in Port-au-Prince, Haiti

Kathleen F Walsh,Myung Hee Lee,Chrispin Chaguza,Widman Pamphile,Gertrude Royal,Vincent Escuyer,Jean W Pape,Daniel Fitzgerald,Ted Cohen,Oksana Ocheretina

DOI: https://doi.org/10.1093/ofid/ofae421

2024-07-18

Open Forum Infectious Diseases

Abstract:Abstract Background Isoniazid-resistant, rifampin-susceptible tuberculosis (Hr-TB) is associated with poor treatment outcomes and higher rates of acquisition of further drug resistance during treatment. Due to a lack of widespread diagnostics, Hr-TB is frequently undetected, and its epidemiology is incompletely understood. Methods We studied the molecular epidemiology of Hr-TB among all patients diagnosed with culture-positive pulmonary tuberculosis between January 1 – June 30, 2017, at an urban referral tuberculosis clinic in Port-au-Prince, Haiti. Demographic and clinical data were extracted from the electronic medical record. Archived diagnostic M. tuberculosis (Mtb) isolates were tested for genotypic and phenotypic isoniazid resistance using the Genotype MTBDRplus assay (Hain, Nehren, Germany) and culture-based testing, respectively. All isoniazid-resistant isolates and a randomly selected subset of isoniazid-susceptible isolates underwent whole genome sequencing (WGS) to confirm the presence of mutations associated with INH resistance, to validate use of Genotype MTBDRplus in this population, and to identify potential transmission links between INH-resistant isolates. Results & Conclusion Among 845 patients with culture-positive pulmonary tuberculosis in Haiti, 65 (7.7%) had Hr-TB based on the Genotype MTBDRplus molecular assay. Age < 20 years old was significantly associated with Hr-TB (OR 2.39; 95% CI 1.14, 4.70; p=0.015). Thirteen (20%) isoniazid-resistant isolates were found in five putative transmission clusters based on a single nucleotide polymorphism distance of < 5. No patients in these transmission clusters were members of the same household. Adolescents are at higher risk for Hr-TB. Strains of isoniazid-resistant M. tuberculosis are actively circulating in Haiti and transmission is likely occurring in community settings.

immunology,infectious diseases,microbiology
Prevalence and incidence of tuberculosis infection among healthcare workers in chest diseases hospitals, Bangladesh: Putting infection control into context

Md Saiful Islam,Emily S Gurley,Sayera Banu,Kamal Hossain,James D Heffelfinger,Kamal Ibne Amin Chowdhury,Shahriar Ahmed,Sadia Afreen,Mohammad Tauhidul Islam,Syed Mohammad Mazidur Rahman,Arfatur Rahman,Michele L Pearson,Shua J Chai,Md. Saiful Islam,Emily S. Gurley,James D. Heffelfinger,Michele L. Pearson,Shua J. Chai

DOI: https://doi.org/10.1371/journal.pone.0291484

IF: 3.7

2023-09-27

PLoS ONE

Abstract:Background Healthcare workers (HCWs) are at increased risk of tuberculosis infection (TBI). We estimated the prevalence and incidence of TBI and risk factors among HCWs in Bangladeshi hospitals to target TB infection prevention and control (IPC) interventions. Methods During 2013–2016, we conducted a longitudinal study among HCWs in four chest disease hospitals. At baseline, we administered a questionnaire on sociodemographic and occupational factors for TB, tuberculin skin tests (TST) in all hospitals, and QuantiFERON ® -TB Gold in-Tube (QFT-GIT) tests in one hospital. We assessed factors associated with baseline TST positivity (induration ≥10mm), TST conversion (induration increase ≥10mm from baseline), baseline QFT-GIT positivity (interferon-gamma ≥0.35 IU/mL), and QFT-GIT conversion (interferon-gamma 20 years had 2.5 (95% CI: 1.3–4.9) times higher odds of QFT-GIT-positivity at baseline compared with those working <10 years. TBI incidence was 4.8/100 person-years by TST and 4.2/100 person-years by QFT-GIT. Females had 8.5 (95% CI: 1.5–49.5) times higher odds of TST conversion than males. Conclusions Prevalent TST and QFT-GIT positivity was associated with an increased number of years working as a healthcare worker and in pulmonary TB wards. The incidence of TBI among HCWs suggests ongoing TB exposure in these facilities and an urgent need for improved TB IPC in chest disease hospitals in Bangladesh.

multidisciplinary sciences
A Systematic Review of Mutations Associated with Isoniazid Resistance Points to Lower Diagnostic Sensitivity for Common Mutations and Increased Incidence of Uncommon Mutations in Clinical Strains of Mycobacterium tuberculosis

Siavash Valafar

DOI: https://doi.org/10.48550/arXiv.2006.00443

2020-05-31

Abstract:Molecular testing is rapidly becoming integral to the global tuberculosis (TB) control effort. Uncommon mechanisms of resistance can escape detection by these platforms and lead to the development of Multi-Drug Resistant (MDR) strains. This article is a systematic review of published articles that reported isoniazid (INH) resistance-conferring mutations between September-2013 and December-2019. The aims were to catalogue mutations associated with INH resistance, estimate their global prevalence and co-occurrence, and their utility in molecular diagnostics. The genes commonly associated with INH resistance, katG, inhA, fabG1, and the intergenic region oxyR-ahpC were considered in this review. In total, 52 articles were included describing 5,632 INHR clinical isolates from 31 countries. The three most frequently mutated loci continue to be katG315 (4,100), inhA-15 (786), and inhA-8 (105). However, the diagnostic value of inhA-8 is far lower than previously thought, only appearing in 25 (0.4%) INHR isolates that lacked a mutation at the first two loci. Importantly, of the four katG loci recommended by the previous systematic review for diagnostics, only katG315 was observed in our INHR isolates. This indicates continued evolution and regional differences in INH resistance. We have identified 58 loci (common to both systematic reviews) in three genomic regions as a reliable basis for molecular diagnostics. We also report 49 new loci associated with INH resistance. Including all observed mutations provides a cumulative sensitivity of 85.1%. The most disconcerting is the remaining 14.9% of isolates that harbor an unknown mechanism of resistance, will escape molecular detection, and likely convert to MDR-TB, further complicating treatment. Integrating the information cataloged in this and other similar studies into current diagnostic tools is essential for combating the emergence of MDR-TB.

Genomics,Populations and Evolution
Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand

Ajala Prommi,Kanphai Wongjarit,Suthidee Petsong,Ubonwan Somsukpiroh,Kiatichai Faksri,Kamon Kawkitinarong,Sunchai Payungporn,Suwatchareeporn Rotcheewaphan

DOI: https://doi.org/10.1128/spectrum.03462-23

IF: 3.7

2024-02-07

Microbiology Spectrum

Abstract:The prevalence of isoniazid-resistant tuberculosis (Hr-TB) is the highest among other types of drug-resistant tuberculosis. Currently, the World Health Organization (WHO) guidelines recommend the treatment of Hr-TB with rifampicin, ethambutol, pyrazinamide, and levofloxacin for 6 months. The susceptibility profiles of Hr-TB clinical isolates, especially when they are co-resistant to second-line drugs, are critical in the selection of the appropriate treatment regimen to prevent treatment failure. This study highlights the susceptibility profiles of the WHO-recommended treatment regimen in Hr-TB clinical isolates from a tertiary care hospital in Thailand and the concordance and importance of using the phenotypic drug susceptibility testing or genotypic drug susceptibility testing for accurate and comprehensive interpretation of results.

microbiology
Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia

Vycke Yunivita,Fajri Gafar,Prayudi Santoso,Lidya Chaidir,Arto Y Soeroto,Triana N Meirina,Lindsey Te Brake,Dick Menzies,Rob E Aarnoutse,Rovina Ruslami

DOI: https://doi.org/10.1093/jac/dkae057

2024-03-09

Journal of Antimicrobial Chemotherapy

Abstract:Abstract Background Pharmacokinetic data on high-dose isoniazid for the treatment of rifampicin-/multidrug-resistant tuberculosis (RR/MDR-TB) are limited. We aimed to describe the pharmacokinetics of high-dose isoniazid, estimate exposure target attainment, identify predictors of exposures, and explore exposure–response relationships in RR/MDR-TB patients. Methods We performed an observational pharmacokinetic study, with exploratory pharmacokinetic/pharmacodynamic analyses, in Indonesian adults aged 18–65 years treated for pulmonary RR/MDR-TB with standardized regimens containing high-dose isoniazid (10–15 mg/kg/day) for 9–11 months. Intensive pharmacokinetic sampling was performed after ≥2 weeks of treatment. Total plasma drug exposure (AUC0–24) and peak concentration (Cmax) were assessed using non-compartmental analyses. AUC0–24/MIC ratio of 85 and Cmax/MIC ratio of 17.5 were used as exposure targets. Multivariable linear and logistic regression analyses were used to identify predictors of drug exposures and responses, respectively. Results We consecutively enrolled 40 patients (median age 37.5 years). The geometric mean isoniazid AUC0–24 and Cmax were 35.4 h·mg/L and 8.5 mg/L, respectively. Lower AUC0–24 and Cmax values were associated (P < 0.05) with non-slow acetylator phenotype, and lower Cmax values were associated with male sex. Of the 26 patients with MIC data, less than 25% achieved the proposed targets for isoniazid AUC0–24/MIC (n = 6/26) and Cmax/MIC (n = 5/26). Lower isoniazid AUC0–24 values were associated with delayed sputum culture conversion (>2 months of treatment) [adjusted OR 0.18 (95% CI 0.04–0.89)]. Conclusions Isoniazid exposures below targets were observed in most patients, and certain risk groups for low isoniazid exposures may require dose adjustment. The effect of low isoniazid exposures on delayed culture conversion deserves attention.

pharmacology & pharmacy,infectious diseases,microbiology
SHORT COMMUNICATION-Pattern of Anti-Tuberculosis Drugs Susceptibility in New and Previously Treated Tuberculosis Patients and Environmental Risk Factors Investigation.

Salma Hameed,Nasir Mahmood,Muhammad Nawaz Chaudhry,Sajid Rashid Ahmad,Mohammad Aqeel Ur Rahman

2019-01-01

Pakistan Journal of Pharmaceutical Sciences

Abstract:Resistance pattern both in newly and previously treated-TB patients and risk factors associated in spread of tuberculosis are investigated in the current study. A total 244 Mycobacterium tuberculosis isolates were used for drug-susceptibility test against four drugs. Environmental risk factors were assessed by using self-designed history proforma. Among 244 TB-isolates, 64% were categorized as MDR-TB in drug-susceptibility test. Male proportion was 51% while 32% belonged to 15-34 years age group and 49% were from city Lahore whereas majority of people (31%) was working on daily wages. Divergent drug-resistance pattern was obtained; RIF (68%), SM (52%), EMB (51%). INH showed only (27%) resistance against first-line anti-TB drug. Drug-resistance prevalence for two drug combination was highest (50%) for (INH+SM) and (INH+EMB) followed by (RIF+SM) (49%) whereas for three drugs combination (INH+RIF+EMB) and (INH+RIF+SM) the prevalence was almost same 50% and 49% respectively while 66% patients were categorized as previously treated and 34% as new TB cases. In drug susceptibility test, 71% were identified as MDR-TB among New TB cases, while 63% were identified as MDR-TB from previously treated cases. Surprisingly DST results displayed that percentage prevalence of MDR-TB both in newly and previously treated cases was almost same.
Establishment and Application of Multi-Pcr-sscp Assay for Rapid Detection of Isoniazid- and Rifampin-Resistance Mycobacterium Tuberculosis Isolates

CHU Mei-fen,YAN Jie,ZHONG Ya-wen,WU Yi-fei,WANG Huan,SUN Ai-hua

DOI: https://doi.org/10.3760/cma.j.issn.0254-5101.2012.07.020

2012-01-01

Abstract:Objective To establish multi-PCR-single strand conformational polymorphism analysis (mPCR-SSCP) for rapid detection of isoniazid (INH) and rifampin (RIF) resistance associated katG,inhA and rpoB genes of Mycobacterium tuberculosis isolates.Methods The INH-and RFP-resistance of 134 isolates was determined by using drug susceptibility test.The primers were designed for detecting INH and RFP resistance-associated katG,inhA and rpoB gene in the isolates by mPCR-SSCP.PCR-DS technique was applied to detect the mutations in katG,inhA and rpoB genes.All the results from different assays were subsequently analyzed as well as compared.Results All of the 134 tested isolates had katG,inhA and rpoB genes.Of the 134 isolates,42 (31.3％) and 45 (33.6％) strains were INH-and RFP-resistant,respectively.The results of mPCR-SSCP and PCR-DS showed that all the 92 INH-susceptible isolates had no mutation in katG and inhA genes with 100％ specificity.In the 89 RFP-susceptible isolates,2 and 1 had mutation in rpoB genes confirmed by mPCR-SSCP and PCR-DS with 97.8％ or 98.9％ specificity,respectively.Among the 42 INH-resistance isolates,33 and 36 strains had the mutations in katG and/or inhA genes due to the results of mPCR-SSCP and PCR-DS with 78.6％ or 85.7％ sensitivity,respectively.The results of mPCR-SSCP and PCR-DS also demonstrated that in the 45 RFP-resistance isolates,41 and 43 strains had the mutations in rpoB gene with 91.1％ or 95.6％ sensitivity,respectively.Conclusion The mPCR-SSCP established in this study can be used to rapidly detect INH and RFP-resistance associated mutations in katG,inhA and rpoB genes of M.tuberculosis with convenience,specificity and sensitivity,which shows a good prospect for application in clinic.
Implementation status of national tuberculosis infection control guidelines in Bangladeshi hospitals

Arifa Nazneen,Sayeeda Tarannum,Kamal Ibne Amin Chowdhury,Mohammad Tauhidul Islam,S. M. Hasibul Islam,Shahriar Ahmed,Sayera Banu,Saiful Islam,Md Saiful Islam

DOI: https://doi.org/10.1371/journal.pone.0246923

IF: 3.7

2021-02-16

PLoS ONE

Abstract:In response to the World Health Organization (WHO) recommendation to reduce healthcare workers’ (HCWs’) exposure to tuberculosis (TB) in health settings, congregate settings, and households, the national TB control program of Bangladesh developed guidelines for TB infection prevention and control (IPC) in 2011. This study aimed to assess the implementation of the TB IPC healthcare measures in health settings in Bangladesh. Between February and June 2018, we conducted a mixed-method study at 11 health settings. The team conducted 59 key-informant interviews with HCWs to understand the status of and barriers impeding the implementation of the TB IPC guidelines. The team also performed a facility assessment survey and examined TB IPC practices. Most HCWs were unaware of the national TB IPC guidelines. There were no TB IPC plans or committees at the health settings. Further, a presumptive pulmonary TB patient triage checklist was absent in all health settings. However, during facility assessment, we observed patient triaging and separation in the TB specialty hospitals. Routine cough-etiquette advice was provided to the TB patients mentioned during the key-informant interviews, which was consistent with findings from the survey. This study identified poor implementation of TB IPC measures in health settings. Limited knowledge of the guidelines resulted in poor implementation of the recommendations. Interventions focusing on the dissemination of the TB IPC guidelines to HCWs along with regular training may improve compliance. Such initiatives should be taken by hospital senior leadership as well as national policy makers.

multidisciplinary sciences
Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas.

Liyu Li,Jianjun Hou,Xinjie Liu,Yujia Guo,Yun Wu,Lihe Zhang,Zhenjun Yang

DOI: https://doi.org/10.1016/j.biomaterials.2014.01.019

IF: 14

2014-04-01

Biomaterials

Abstract:
Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014

Jose Gabriel Cornejo Garcia,Valentina Antonieta Alarcón Guizado,Alberto Mendoza Ticona,Edith Alarcon,Einar Heldal,David A J Moore

DOI: https://doi.org/10.1371/journal.pone.0206658

IF: 3.7

2018-12-04

PLoS ONE

Abstract:Background: Resistance to isoniazid is the most common form of drug-resistance in tuberculosis. However only a tiny proportion of TB patients in the world have access to isoniazid drug susceptibility testing-the widely implemented Xpert MTB/RIF technology only tests for resistance to rifampicin. Patients with isoniazid mono resistance that is not identified at baseline are treated with a standard regimen that effectively results in rifampicin mono-therapy during the latter four months of the six month treatment course, exposing remaining viable organisms to a single agent and greatly increasing the risk of development of multi drug-resistant TB. Unusually, Peru has pioneered universal pre-treatment drug susceptibility testing with methods that identify isoniazid resistance and has thus identified a large number of individuals requiring tailored therapy. Since 2010, treatment in Peru for isoniazid-resistant tuberculosis without multidrug-resistant tuberculosis (Hr-TB) has been with a standardized nine-month regimen of levofloxacin, rifampicin, ethambutol and pyrazinamide. The objectives of this study were to evaluate the outcomes of treatment for patients with Hr-TB initiating treatment with this regimen between January 2012 and December 2014 and to determine factors affecting these outcomes. Methods: Retrospective cross-sectional study; case data were obtained from the national registry of drug-resistant tuberculosis. Patients diagnosed with isoniazid resistant TB without resistance to rifampicin, pyrazinamide, ethambutol and quinolones as determined by either a rapid drug susceptibility testing (DST) (nitrate reductase test, MODS, Genotype MTBDRplus) or by the proportion method were included. Findings: A total of 947 cases were evaluated (a further 403 without treatment end date were excluded), with treatment success in 77.2% (731 cases), loss to follow-up in 19.7% (186 cases), treatment failure in 1.2% (12 cases), and death in 1.9% (18 cases). Unfavorable outcomes were associated in multivariate analysis with male gender (OR 0.50, 95% CI 0.34-0.72, p<0.05), lack of rapid DST (OR 0.67, 95% CI 0.50-0.91, p = 0.01), additional use of an injectable second-line anti-tuberculous drug (OR 0.46, 95% CI 0.31-0.70, p<0.05), and treatment initiation in 2014 (OR 0.77, 95% CI 0.62-0.94, p = 0.01). Interpretation: The treatment regimen implemented in Peru for isoniazid resistant TB is effective for TB cure and is not improved by addition of an injectable second-line agent. Access to rapid DST and treatment adherence need to be strengthened to increase favorable results.
Detection of katG, inhA and ahpC gene mutation in clinical isolates of isoniazid-resistant Mycobacterium tuberculosis in Makassar City, South Sulawesi, Indonesia

Muhammad Azron Junaedi,Muhammad Nasrum Massi,Rizalinda Sjahril,Handayani Halik,Zainul Muttaqin,Nurul Rifqiani,Nur Irma Safitri,Mayabi Pratika,Itzar Chaidir Islam,Firdaus Hamid,Rosdiana Natzir,Ahyar Ahmad

DOI: https://doi.org/10.1016/j.ijtb.2023.03.019

Abstract:Background: Tuberculosis (TB) is an airborne disease caused by Mycobacterium tuberculosis (M. tuberculosis). The world is currently facing challenges due to the spread of anti-tuberculosis drug-resistant of M. tuberculosis. Isoniazid-resistant (INH), is one of the first-line anti-tuberculosis agents that has a high resistance case. This study used Multiplex allele-specific Polymerase Chain Reaction (MAS-PCR) to detect the most common mutations associated with isoniazid resistance on inhA, katG, and ahpC gene. Methods: This study used samples from clinical isolates of M. tuberculosis which had been tested for their antibiotic sensitivity of first-line anti-tuberculosis drugs. The DNA extraction process was carried out using the boiling method and then amplified with specific primers for inhA, katG, and ahpC genes using the MAS-PCR method. The results are then read on the electrophoretic gel with an interpretation of the mutation gene when the target gene DNA bands were absent according to the allele-specific fragments target. Results: A total of 200 isolates were tested in this study consisting of isoniazid-resistant and susceptible with the largest distribution of Multi-Drug Resistant (MDR) isolates with a total of 146 isolates (73%). The most significant gene mutation was on the ahpC gene in 61 isolates (30,5%) and the combination mutation of the katG + ahpC gene in 52 isolates (26%) with sensitivity and specificity of the test reaching 87% and 42% for the detection of INH-resistant. Conclusion: Mutation on the ahpC gene has the highest percentage in this study. AhpC gene can be considered one of the essential genes to be tested for the cause of isoniazid-resistant. Using MAS-PCR for detecting gene mutation in isoniazid-resistant was simple and easy, it has the potential to be widely used as a rapid screening molecular test.
Detection of Rifampicin Resistance rpoB Gene Using GeneXpert MTB/RIF Assay in Pulmonary Tuberculosis Cases at Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia

Bekele Sharew,Ayenew Berhan,Andargachew Almaw,Mulat Erkihun,Tegenaw Tiruneh,Teklehaimanot Kiros,Yenealem Solomon,Mitikie Wondmagegn,Etenesh Wondimu,Abay Teshager,Simegnew Bihonegn,Mihret Tilahun,Birhanu Getie

DOI: https://doi.org/10.1002/jcla.25111

IF: 3.124

2024-10-12

Journal of Clinical Laboratory Analysis

Abstract:According to the examined records, a total of 12,891 presumed pulmonary tuberculosis cases sought TB diagnosis services utilizing the GeneXpert system assay, which was included in this retrospective analysis. Of the total presumptive pulmonary TB patients in the research period, 8.9% (1160/12,891) tested positive for M. tuberculosis, while 7.1% (82/1160) were rifampicin‐resistant. Background Tuberculosis (TB) is a preventable and treatable disease leading to the second death globally. The evolution of drug resistance in Mycobacterium tuberculosis (MTB), particularly rifampicin resistance (RR), has hampered TB control efforts. Thus, this study aimed to provide information regarding the magnitude of MTB and rifampicin resistance among patients tested using the GeneXpert method. Methods A retrospective analysis was carried out at DTCSH. The study included TB registration logbook data from all patients who visited the hospital and were tested for MTB with the Xpert MTB/RIF assay from 2017 to 2024. The laboratory‐based data were entered, cleaned, and analyzed using SPSS version 26 software. Multilogistic regression analysis was employed, and a p value ≤ 0.05 was considered statistically significant. Results A total of 12,981 patient results were included, of which 8.9% (1160/12,981) were MTB‐positive and 7.1% (82/1160) were RR. Individuals aged 15–29 years (AOR = 2.13; 95% CI = 1.55–2.93, p

medical laboratory technology
HSJ people. Cast adrift.

J. Fagan

2004-02-12

Abstract:
Rifampicin tolerance and growth fitness among isoniazid-resistant clinical isolates: an in-vitro longitudinal study

Srinivasan Vijay,Nguyen Le Hoai Bao,Dao Nguyen Vinh,Le Thanh Hoang Nhat,Do Dang Anh Thu,Nguyen Le Quang,Le Pham Tien Trieu,Hoang Ngoc Nhung,Vu Thi Ngoc Ha,Phan Vuong Khac Thai,Dang Thi Minh Ha,Nguyen Huu Lan,Maxine Caws,Guy E. Thwaites,Babak Javid,Nguyen Thuy Thuong Thuong

DOI: https://doi.org/10.1101/2023.11.22.568240

2024-05-04

Abstract:Antibiotic tolerance in leads to less effective bacterial killing, poor treatment responses and resistant emergence. Therefore, we investigated the rifampicin tolerance of isolates, with or without pre-existing isoniazid-resistance. We determined the rifampicin survival fraction by minimum duration of killing assay in isoniazid susceptible (IS, n=119) and resistant (IR, n=84) isolates. Then we correlated the rifampicin tolerance with bacterial growth, rifampicin minimum inhibitory concentrations (MICs) and isoniazid-resistant mutations. The longitudinal IR isolates collected from patients were analyzed for changes in rifampicin tolerance and associated emergence of genetic variants. The median duration of rifampicin exposure reducing the surviving fraction by 90% (minimum duration of killing-MDK90) increased from 1.23 (95%CI 1.11; 1.37) and 1.31 (95%CI 1.14; 1.48) to 2.55 (95%CI 2.04; 2.97) and 1.98 (95%CI 1.69; 2.56) days, for IS and IR respectively, during 15 to 60 days of incubation. This indicated the presence of fast and slow growing tolerant sub-populations. A range of 6 log -fold survival fraction enabled classification of tolerance as low, medium or high and revealed IR association with increased tolerance with faster growth (OR=2.68 for low vs. medium, OR=4.42 for low vs. high, -trend=0.0003). The high tolerance in IR isolates was specific to those collected during rifampicin treatment in patients and associated with bacterial genetic microvariants. Furthermore, the high rifampicin tolerant IR isolates have survival potential similar to multi-drug resistant isolates. These findings suggest that IR tuberculosis needs to be evaluated for high rifampicin tolerance to improve treatment regimen and prevent the risk of MDR-TB emergence.

Microbiology

Concerning the existence of a suppressor mechanism, "4-s", in the unanesthetized human.

Molecular Detection of Isoniazid, Rifampin and Ethambutol Resistance to M. Tuberculosis and M. Bovis in Multidrug Resistant Tuberculosis (MDR-TB) Patients in Pakistan.

Targeted next-generation sequencing of Mycobacterium tuberculosis from patient samples: lessons learned from high drug-resistant burden clinical settings in Bangladesh

Restricted transition probabilities and their applications to some problems in the dynamics of biological populations.

New Zealand's neurologist workforce: a pragmatic analysis of demand, supply and future projections.

Proceedings: Contraceptive steroids and breast cancer.

The molecular basis for prognosis of isoniazid resistance in Mycobacterium tuberculosis

Molecular epidemiology of isoniazid-resistant M. tuberculosis in Port-au-Prince, Haiti

Prevalence and incidence of tuberculosis infection among healthcare workers in chest diseases hospitals, Bangladesh: Putting infection control into context

A Systematic Review of Mutations Associated with Isoniazid Resistance Points to Lower Diagnostic Sensitivity for Common Mutations and Increased Incidence of Uncommon Mutations in Clinical Strains of Mycobacterium tuberculosis

Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand

Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia

SHORT COMMUNICATION-Pattern of Anti-Tuberculosis Drugs Susceptibility in New and Previously Treated Tuberculosis Patients and Environmental Risk Factors Investigation.

Establishment and Application of Multi-Pcr-sscp Assay for Rapid Detection of Isoniazid- and Rifampin-Resistance Mycobacterium Tuberculosis Isolates

Implementation status of national tuberculosis infection control guidelines in Bangladeshi hospitals

Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas.

Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014

Detection of katG, inhA and ahpC gene mutation in clinical isolates of isoniazid-resistant Mycobacterium tuberculosis in Makassar City, South Sulawesi, Indonesia

Detection of Rifampicin Resistance rpoB Gene Using GeneXpert MTB/RIF Assay in Pulmonary Tuberculosis Cases at Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia

HSJ people. Cast adrift.

Rifampicin tolerance and growth fitness among isoniazid-resistant clinical isolates: an in-vitro longitudinal study